Show simple item record

dc.contributor.authorVuyolwethu Khwaza
dc.contributor.authorSithenkosi Mlala
dc.contributor.authorOpeoluwa O. Oyedeji
dc.contributor.authorBlessing A. Aderibigbe
dc.contributor.otherDepartment of Chemistry, University of Fort Hare, Alice Campus, Alice 5700, Eastern Cape, South Africa
dc.contributor.otherDepartment of Chemistry, University of Fort Hare, Alice Campus, Alice 5700, Eastern Cape, South Africa
dc.contributor.otherDepartment of Chemistry, University of Fort Hare, Alice Campus, Alice 5700, Eastern Cape, South Africa
dc.contributor.otherDepartment of Chemistry, University of Fort Hare, Alice Campus, Alice 5700, Eastern Cape, South Africa
dc.date.accessioned2025-10-09T05:30:14Z
dc.date.available2025-10-09T05:30:14Z
dc.date.issued01-04-2021
dc.identifier.urihttps://www.mdpi.com/1420-3049/26/9/2401
dc.identifier.urihttp://digilib.fisipol.ugm.ac.id/repo/handle/15717717/41097
dc.description.abstractPentacyclic triterpenoids are well-known phytochemicals with various biological activities commonly found in plants as secondary metabolites. The wide range of biological activities exhibited by triterpenoids has made them the most valuable sources of pharmacological agents. A number of novel triterpenoid derivatives with many skeletal modifications have been developed. The most important modifications are the formation of analogues or derivatives with nitrogen-containing heterocyclic scaffolds. The derivatives with nitrogen-containing heterocyclic compounds are among the most promising candidate for the development of novel therapeutic drugs. About 75% of FDA-approved drugs are nitrogen-containing heterocyclic moieties. The unique properties of heterocyclic compounds have encouraged many researchers to develop new triterpenoid analogous with pharmacological activities. In this review, we discuss recent advances of nitrogen-containing heterocyclic triterpenoids as potential therapeutic agents. This comprehensive review will assist medicinal chemists to understand new strategies that can result in the development of compounds with potential therapeutic efficacy.
dc.language.isoEN
dc.publisherMDPI AG
dc.subject.lccOrganic chemistry
dc.titlePentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery
dc.typeArticle
dc.description.keywordspentacyclic triterpenoids
dc.description.keywords<i>N</i>-heterocycles
dc.description.keywordshybrids
dc.description.keywordsderivatives
dc.description.keywordsanticancer
dc.description.keywordsoleanolic acid
dc.description.doi10.3390/molecules26092401
dc.title.journalMolecules
dc.identifier.e-issn1420-3049
dc.identifier.oaioai:doaj.org/journal:f1a24562d4ba4fbcb027150b4bd9ce78
dc.journal.infoVolume 26, Issue 9


This item appears in the following Collection(s)

Show simple item record